Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.76 USD | -3.16% | +2.60% | -17.86% |
May. 14 | Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises | MT |
May. 14 | Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M | MT |
Financials (USD)
Sales 2024 * | 74.39M | Sales 2025 * | 28.75M | Capitalization | 268M |
---|---|---|---|---|---|
Net income 2024 * | -152M | Net income 2025 * | -226M | EV / Sales 2024 * | 3.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9.31 x |
P/E ratio 2024 * |
-1.92
x | P/E ratio 2025 * |
-1.54
x | Employees | 335 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.34% |
1 day | -3.16% | ||
1 week | +2.60% | ||
Current month | -7.69% | ||
1 month | -5.48% | ||
3 months | -14.81% | ||
6 months | -9.21% | ||
Current year | -17.86% |
Managers | Title | Age | Since |
---|---|---|---|
Kristin Yarema
CEO | Chief Executive Officer | 53 | 23-03-31 |
Johanna Mylet
DFI | Director of Finance/CFO | 37 | 15-05-31 |
Mark Gergen
CHM | Chairman | 61 | 18-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marcea Lloyd
BRD | Director/Board Member | 75 | 18-12-31 |
Cynthia Collins
BRD | Director/Board Member | 65 | 21-07-22 |
Mark Gergen
CHM | Chairman | 61 | 18-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.87% | 2 M€ | -25.75% | ||
0.03% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-14 | 2.76 | -3.16% | 98,022 |
24-06-13 | 2.85 | +1.79% | 101,012 |
24-06-12 | 2.8 | +1.82% | 298,529 |
24-06-11 | 2.75 | +3.97% | 250,244 |
24-06-10 | 2.645 | -1.67% | 309,444 |
Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.86% | 268M | |
+18.15% | 124B | |
+18.02% | 112B | |
-12.75% | 22.22B | |
+5.07% | 22.94B | |
-39.94% | 16.87B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- PSTX Stock